Abstract
Therapy for Pseudomonas aeruginosa infections is hard due to its high natural and acquirable antibiotic resistance. After colonization in the hosts, P. aeruginosa commonly accumulates genomic mutations which confer them antibiotic resistance and better adaptations to the host environment. Deciphering the mechanisms of antibiotic resistance development in the clinical setting may provide critical insights into the design of effective combinatory antibiotic therapies to treat P. aeruginosa infections. In this work, we demonstrate a resistance mechanism to aztreonam of a clinical isolate (ARP36) in comparison with a sensitive one (CSP18). RNAseq and genomic DNA resequencing were carried out to compare the global transcriptional profiles and in the clinical setting genomic profiles between these two isolates. The results demonstrated that hyperexpression of an efflux pump MexAB-OprM caused by a R70Q substitution in MexR, contributed to the increased resistance to aztreonam in the isolate ARP36. Simulation of mexR of ARP36 by gene editing in CSP18 conferred CSP18 an ARP36-like susceptibility to the aztreonam. The R70Q substitution prevented MexR from binding to the intergenic region between mexR and mexAB-oprM operon, with no impact on its dimerization. The presented experimental results explain for the first time why the clinically relevant R70Q substitution in the MexR derepresses the expression of mexAB-oprM in P. aeruginosa.
Introduction
Pseudomonas aeruginosa, an opportunistic human pathogen, is a leading cause of both community-acquired and hospital-acquired infection all around the world (). Infections by this bacterium are often difficult to cure because of its natural and acquirable resistance to a wide range of antibiotics, leaving a limited number of effective antimicrobial agents. The natural antibiotic resistance of P. aeruginosa is attributable to its low outer membrane permeability as well as to the expression of multidrug efflux pumps, such as MexAB-OprM (; ; ). Of note, in addition to contributing to the natural resistance due to its constitutive expression, the MexAB-OprM is also hyperexpressed via mutations in nalB, nalC, or nalD, conferring multidrug-resistant phenotype (; Srikumar et al., 2000; ; ; ; ). Once infection is established, P. aeruginosa strains usually develop antibiotic resistance during antimicrobial treatment, and the same P. aeruginosa lineage typically persists in the patient (; Burns et al., 2001).
Aztreonam is a fully synthetic β-lactam antibiotic, with a high binding affinity for penicillin-binding protein 3 (PBP3) and high stability against hydrolysis by a wide range of β-lactamases (). It has been approved in an inhaled formulation in treatment for cystic fibrosis patients with P. aeruginosa infection since 2010 (). It has been shown that the inhaled aztreonam is an effective and safe antimicrobial drug to eradicate the newly acquired P. aeruginosa and for long-term suppressive treatment for chronic endobronchial infections in CF patients (). However, as for all antimicrobial agents, P. aeruginosa can develop aztreonam resistance that decreases its effectiveness (). Although a few mechanisms of aztreonam resistance have been identified via in vitro evolution (; ; ), understanding of the mechanisms for aztreonam resistance in the clinical setting is limited and needs to be further explored ().
In this study, we obtained two clinical strains of P. aeruginosa from a patient with ulcerative colitis before and after therapy with cefoxitin. The early strain was isolated soon after the patient was admitted to the hospital, while the later one was isolated after the antibiotic therapy for 7 days. The early isolate CSP18 [named as CSP18 due to its sensitivity to ciprofloxacin in our earlier study (Xu et al., 2020a)]was susceptible to aztreonam, while the later one ARP36 was aztreonam resistant. Therefore, we wanted to explore the molecular mechanisms of aztreonam resistance in the resistant clinical isolate in comparison with the sensitive one in the clinical setting. The results presented in this study demonstrate that hyperexpression of the mexAB-oprM caused by a R70Q substitution in MexR is the contributory factor for this conversion. Furthermore, we have revealed that R70Q substitution in the MexR had no impact on its dimerization, rather it impaired its binding capability to the intergenic region between mexR and mexAB-oprM operon, thus derepressed the expression of mexAB-oprM operon. Our research provides further insights into the molecular mechanism of aztreonam resistance in P. aeruginosa under clinical setting.
Materials and Methods
Basic Characterization of the Bacterial Isolates
Bacterial strains and plasmids for this work are listed in Supplementary Table 1. Aztreonam-susceptible (CSP18) and aztreonam-resistant (ARP36) P. aeruginosa strains used in this work were isolated respectively from sputum and abdominal drainage of a patient with ulcerative colitis before and after 7-day therapy with cefoxitin, which was used as an empirical anti-infective drug. Species of these two isolates were identified by PCR amplification with primers (Supplementary Table 2) and sequence analysis of 16S rDNA (). Random amplified polymorphic DNA (RAPD) typing was conducted with indicated primer (Supplementary Table 2) according to a previous study (). The allelic profiles of the P. aeruginosa isolates were determined by multilocus sequence typing (MLST) analysis following previous description (). Briefly, chromosomal DNAs were isolated from overnight cultures of P. aeruginosa strains using DNA purification kit (Tiangen Biotec, Beijing, China) and utilized as PCR templates. The internal fragments of aroE, mutL, acsA, guaA, nuoD, trpE, and ppsA genes were amplified with PCR, sequenced with indicated primers (shown in Supplementary Table 2), and the sequences were then submitted to the P. aeruginosa MLST database1 to obtain the allelic numbers. A sequence type (ST) was assigned to CSP18 or ARP36 by combination of the seven allelic numbers. Minimum inhibitory concentration (MIC) against antibiotics was tested by a twofold serial dilution method described before with the exception that the bacteria were cultured in LB broth (), and susceptibility to aztreonam was interpreted based on the Clinical and Laboratory Standards Institute guidelines (CLSI 2011–2018).
Construction of Plasmids
To overexpress mexR, a 495 bp mexR-containing fragment was amplified with PCR using CSP18 and ARP36 genomic DNA as templates (primers listed in Supplementary Table 2). The resulting PCR products were digested with EcoRI and BamHI, and then inserted into pUCP24, leading to pUCP24-mexRCSP18 and pUCP24-mexRARP36, respectively. For the expression of C-terminal His-tagged MexR in Escherichia coli, the open reading frame of mexR without its stop codon was amplified with PCR using CSP18 and ARP36 genomic DNA as templates (primers listed in Supplementary Table 2). The resulting PCR products were digested with XhoI and BamHI, and then inserted into an expression vector pET28a, leading to pET28a-mexRCSP18 and pET28a-mexRARP36, respectively. For bacterial two-hybrid assay, the mexR gene of CSP18 and ARP36 were amplified with the indicated primers (Supplementary Table 2) and respectively cloned into the prey vector (pTRG) and bait vector (pBT).
To make the mexR (MexR R70Q) point mutation construct, a 1,135 bp DNA fragment containing mexR and partial immediately adjacent genes (pasP and mexA) was PCR amplified using ARP36 genomic DNA as templates (primers listed in Supplementary Table 2), digested with BamHI and EcoRI, and then inserted into a pEX18Tc vector, resulting in pEX18-mexRARP36. Gene editing in CSP18 was carried out by conjugal transfer of this plasmid followed by selection for single crossover and then double crossover, as early described (). The target strain with MexR R70Q point mutation was confirmed by PCR amplification and sequencing analysis (primers in Supplementary Table 2).
Total RNA Isolation, RT-qPCR, and RNAseq Analysis
Total RNA isolation and RT-qPCR were carried out as described in our early studies (Xu et al., 2020a; Xu et al., 2020b). Overnight bacterial strains were subcultured to the log phase (OD600 = 1.0) at 37°C. Total RNA was extracted using RNAprep Pure Cell/Bacteria Kit (Tiangen Biotec, Beijing, China) and dissolved into RNase free water. cDNAs were synthesized with random primers and PrimeScript Reverse Transcriptase (Takara, Dalian, China) and mixed with specific primers (Supplementary Table 2) and SYBR premix Ex Taq II (Takara, Dalian, China). Quantitative PCR was carried out in a CFX Connect Real-Time Machine (Bio-Rad, Hercules, CA, United States). As an internal control, rpsL, encoding a 30S ribosomal protein was utilized.
RNAseq was performed as described before (Xu et al., 2020a,b). The quality and quantity of total RNAs from CSP18 and ARP36 were determined with a Bioanalyzer 2100 system (Agilent Technologies, Palo Alto, CA, United States), a NanoDrop spectrophotometer, and electrophoresis on a 1% (wt/vol) agarose gel. A Ribo-Zero rRNA Removal Kit (Bacteria, Illumina, San Diego, CA, United States) was used to remove rRNA. After that, mRNA was fragmented and reverse transcribed to synthesize the double-strand cDNA, followed by purification, ends repair, and ligation with adaptors. After 11 cycle PCR reaction, the products were purified, qualified, and quantified using a Bioanalyzer 2100 system (Agilent), and a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA, United States). The resulting DNA libraries were then sequenced using an HiSeq 2500 platform (Illumina) with a 2 × 150 paired-end configuration.
Sequencing reads were mapped onto the reference genome of PAO1 (NC_002516.2) with Bowtie2 (v2.1.9). Gene expressional values were then analyzed by software HTSeq (v0.6.1p1). Differentially expressed genes were identified with the DESeq software, with a cut-off of fold-change more than 2 and p-value no larger than 0.05.
DNA Purification and Resequencing
DNA purification and resequencing were conducted as previously described (Xu et al., 2020a,b). Genomic DNA of bacterial strains was extracted with DNA isolation kit (Tiangen Biotec, Beijing, China). Fragments shorter than 500 bp in length were recovered from 200 ng chromosomal DNA using sonication (Covaris S220), ends treated, and then ligated with an adaptor. The fragments ∼470 bp were purified with beads and then amplified in a six-cycle PCR reaction. The products were purified with beads, qualified, and quantified with a Qsep100 machine (Bioptic, Taiwan, China) and a Qubit3.0 Fluorometer (Invitrogen). The generating libraries were sequenced on a Hiseq machine (Illumina) with a 2 × 150 paired-end (PE) configuration following manufacturer’s instructions (Illumina). The sequencing reads were mapped onto the reference genome of PAO1 (NC_002516.2) via a BWA software (version 0.7.12). Single nucleotide variation (SNV) and InDel mutation were analyzed with the software Samtools (version 1.1) and the Unified Genotyper module from GATK.
Expression and Purification of MexR-His
MexR-His recombinant protein was purified as previously described with a minor modification (). Briefly, an overnight culture of E. coli BL21/DE3 containing plasmid pET28a-mexRCSP18 or pET28a-mexRARP36 was diluted 50-fold into 100 ml of L-broth supplemented with kanamycin (50 μg/ml) and grown at 37°C until the culture reached an OD600 of 0.4–0.6. Expression of MexR-His was then induced by adding isopropyl-β-D-thiogalactoside (IPTG) at a final concentration of 0.1 mM and growing for another 4 h. The bacterial cells were collected by centrifugation at 8,000 × g for 10 min at 4°C and resuspended in the lysis buffer (50 mM Na2HPO4, 50 mM NaH2PO4, 0.3 M NaCl), followed by sonication until the suspension became limpid. The recombinant MexR-His was Ni-affinity purified from soluble fraction following the manufacturer’s instruction (Qiagen). The purified protein was eluted with lysis buffer containing 300 mM imidazole, examined by SDS-PAGE, quantified by Nanodrop, and stored at 4°C.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSA) was carried out as described before with minor modification (Zheng et al., 2018). Briefly, DNA fragments of the intergenic region of mexA-mexR were PCR amplified with indicated primers (Supplementary Table 2). DNA fragments (0.35 μM) were incubated with purified MexR-His protein (0–36 μM) in a 20 μl reaction system (50 mM Tris, 0.5 M EDTA, 50 mM NaCl, 2.5% glycerol, pH 7.9) at 37°C for 30 min. Samples were loaded onto an 8% native polyacrylamide gel in 0.5 × Tris-Borate-EDTA (TBE) buffer which had been prerun on ice for 1 h and electrophoresed on ice for 1.5 h at 120 V. The gel was then stained with 0.5 μg/ml ethidium bromide in a 0.5 × TBE buffer and visualized in an imager ChemiDocTM XRS + (Bio-Rad).
Microscale Thermophoresis Analysis
The microscale thermophoresis analysis (MST) experiments were conducted on Monolith NT.115 instrument (NanoTemper, München, Germany) according to the manufacture’s instruction. A DNA fragment corresponding to the intergenic region of mexR-mexA was PCR amplified with primers shown in Supplementary Table 2. The proteins MexRCSP18 and MexRARP36 were labeled with NT-647-NHS as aptamer probes. Samples containing 352 nM labeled MexRCSP18 or MexRARP36 and serial twofold increasing concentrations of DNA fragments (0.488–16,000 nM) in binding buffer (10 mM Tris, 1 mM DTT) were loaded on standard treated silicon capillaries (NanoTemper Technologies). Thermophoresis was measured with a Monolith NT.115 instrument at room temperature using 20% light-emitting diode (LED) and 60% MST power. Data were analyzed using MO affinity analysis software.
Other Methods
The β-galactosidase activity was measured as described previously (Weng et al., 2016). Assays for protein-protein interaction by bacterial two-hybrid system were performed according to the protocol supplied by the manufacturer (Stratagene, La Jolla, CA, United States).
Statistical Analysis
Statistical analyses were performed using Graphpad software. Student’s t-test (two-tailed) was utilized to assess the statistical significance of two-group comparisons.
Ethics Statement
We have a waiver from the medical ethics committee of Tianjin Union Medical Center, exempting this study from the requirement to have ethics approval and written informed consent as the clinical strains used in this work come from the routine procedures of the clinical laboratory rather than the clinical trials.
Results and Discussion
Clinical Isolates CSP18 and ARP36 Belong to the Same Clone
Sputum and abdominal drainage samples were collected from a patient with ulcerative colitis before and after therapy for 7 days with cefoxitin. Two P. aeruginosa strains were isolated, the early one before the antibiotic therapy which was susceptible to aztreonam (CSP18), and the later one after the antibiotic therapy which was resistant against aztreonam (ARP36) (Table 1). PCR examination and sequencing analysis for the 16S rDNAs revealed that both of them were P. aeruginosa (Figure 1A) (). The allelic profile of guaA, mutL, nuoD, acsA, aroE, ppsA, and trpE genes were revealed as 12, 98, 4, 17, 5, 14, and 10, respectively by MLST analysis, representing the same sequence type, ST611. A RAPD typing was further conducted on the CSP18 and ARP36 strains, which in combination with MLST analysis indicated that they belonged to the same clone (Figure 1B).
TABLE 1
| Strains | Azta,b | Cazb | Memb | Fepb | Pipb | Chlb | Cipb | Oflb | Foxb |
| CSP18 | 4 | 1 | 0.5 | 1 | 16 | 64 | 0.25 | 1 | 2,048 |
| ARP36 | 32 | 4 | 2 | 4 | 64 | 256 | 1 | 4 | 2,048 |
| CSP18/pUCP24 | 4 | 1 | 0.5 | 1 | 16 | 64 | 0.25 | 1 | 2,048 |
| ARP36/pUCP24 | 32 | 4 | 2 | 4 | 64 | 256 | 1 | 4 | 2,048 |
| CSP18/mexRCSP18 | 4 | 1 | 0.5 | 1 | 16 | 64 | 0.25 | 1 | 2,048 |
| CSP18/mexRARP36 | 8 | 2 | 1 | 2 | 32 | 128 | 0.5 | 2 | 2,048 |
| ARP36/mexRCSP18 | 16 | 2 | 1 | 2 | 32 | 128 | 0.5 | 2 | 2,048 |
| ARP36/mexRARP36 | 32 | 4 | 2 | 4 | 64 | 256 | 1 | 4 | 2,048 |
| CSP18mexRARP36 | 32 | 4 | 2 | 4 | 64 | 256 | 1 | 4 | 2,048 |
MICs (μg/ml) of indicated P. aeruginosa strains.
aClinical Laboratory Standards Institute (CLSI) susceptibility breakpoints: aztreonam ≤ 8 μg/ml; resistance breakpoints: aztreonam ≥ 32 μg/ml.bAzt, aztreonam; Caz, ceftazidime; Mem, meropenem; Fep, cefepime; Pip, piperacillin; Chl, chloramphenicol; Cip, ciprofloxacin; Ofl, ofloxacin; Fox, cefoxitin.
FIGURE 1
Isolate ARP36 Is Resistant to Aztreonam
Aztreonam is an effective anti-P. aeruginosa drug (), and aztreonam susceptibility of CSP18 and ARP36 were different based on the preliminary examination with VITEK automatic microbe analysis instrument (data not shown). Therefore, their susceptibilities to aztreonam were further examined with the twofold serial dilution method (). As shown in Table 1, CSP18 (the early isolate) was found to be susceptible to aztreonam, with MIC of 4 μg/ml, while the later one (ARP36) displayed resistance to aztreonam, with MIC of 32 μg/ml, representing an eightfold increase (Table 1).
An Operon Encoding MexAB-OprM Efflux Pump Is Upregulated in ARP36
To explore the mechanisms of reduced susceptibility to aztreonam in the isolate ARP36, RNAseq was performed and the global gene expression profiles were compared between the strains CSP18 and ARP36. mRNA levels of 30 genes were significantly altered between these two isolates (Supplementary Table 3). Among them, genes encoding efflux pump MexAB-OprM, mexA, mexB, and oprM, displayed eight-, seven-, and sevenfold higher mRNA levels, respectively, in ARP36 than those in CSP18 (Supplementary Table 3). To validate the increased transcriptional level, we further examined and compared the mRNA levels of mexAB-oprM operon between CSP18 and ARP36 by real-time qPCR. Consistent with the RNAseq results, the mRNA level of mexB showed a significant increase in ARP36 compared with that in CSP18 (Figure 2A). To further confirm the increased expression level of the mexAB-oprM, PmexA-lacZ reporter construct was transformed into the CSP18 and ARP36 strains and their β-galactosidase activities were measured. As shown in Figures 2B,E, the ARP36 strain displayed an increased β-galactosidase activity, which further conformed with the RNAseq and real-time qPCR results. In addition, the transcriptional level of mexR, encoding a repressor for the mexAB-oprM operon (), displayed a 15-fold increase in the ARP36 strain in comparison with the CSP18 strain in the RNAseq results (Supplementary Table 3). The increased mRNA level of mexR was further confirmed by the real-time qPCR (Figure 2A).
FIGURE 2
It has been reported that MexAB-OprM efflux pump can export a large number of antibiotics belonging to different classes, including β-lactams, fluoroquinolones, and chloramphenicol (). Therefore, we also examined the sensitivity of CSP18 and ARP36 against ceftazidime, meropenem, piperacillin, cefepime, chloramphenicol, ciprofloxacin, and ofloxacin. Similar to aztreonam, ARP36 showed reduced susceptibility to all of these antibiotics, with an average fourfold increase in MIC against them (Table 1). However, the ARP36 displayed a similar susceptibility to cefoxitin as the CSP18 (Table 1), which suggested that cefoxitin may not be a substrate for the MexAB-OprM efflux pump. Of note, while cefoxitin is not an antipseudomonal antibiotic, it has been reported to induce expression of ampC strongly in P. aeruginosa (). However, the selective pressure of cefoxitin for the aztreonam resistance development remains elusive. In addition, other factors, such as the inflammatory response, nutrient availability, and oxygen levels in the ulcer location of the host may also contribute to this development.
An Amino Acid Substitution in MexR Contributes to the Upregulation of mexAB-oprM and Increased Resistance to Aztreonam in ARP36
To further explore the molecular mechanism for the increased resistance against aztreonam in ARP36, as well as the increased expression of the mexAB-oprM operon, DNA resequencing was conducted to determine mutations in the genome of ARP36 relative to that of the CSP18 strain, with PAO1 as reference genome2. Between CSP18 and ARP36, there were 207 variants, among which 76 variants were heterozygous (Supplementary Table 4), suggesting they may occur during the culture in vitro before the DNA extraction. According to the DNA resequencing results, 28 genes had insertions or deletions, while 16 genes had non-synonymous single nucleotide variation (SNV) (Supplementary Table 4). Among them, a G209A substitution in the mexR gene resulted in a R70Q substitution in the MexR protein of the ARP36 strain in comparison with that of CSP18 (Supplementary Table 4). To validate the mutation, mexR genes were amplified by PCR from the genomic DNA of strains CSP18 and ARP36 and cloned into pUCP24 vectors. The mexR clones were sequenced and aligned with the mexR gene of PAO1 reference strain2. Sequence analysis revealed that mexR in CSP18 was the same as that of PAO1 reference2, while mexR from ARP36 showed a G209A substitution, which confirmed the results of genome resequencing.
MexR, a MarR family transcriptional regulator, is known to repress the expression of mexAB-oprM and itself in P. aeruginosa (). Mutations in the MexR lead to mexAB-oprM hyperproduction, and an attendant increased antibiotics resistance had been reported previously (Ziha-Zarifi et al., 1999; ; ). To assess if the R70Q substitution in MexR contributed to the increased expression of mexAB-oprM operon as well as the decreased susceptibility to aztreonam in the ARP36 strain, the mexR gene from both CSP18 and ARP36 were overexpressed in the ARP36 strain background. The mRNA levels of mexB were compared by real-time qPCR. As the results shown in Figure 2C, introduction of the mexRCSP18, but not mexRARP36, decreased the relative mRNA levels of mexBARP36. Also, PmexA-lacZ reporter assay further confirmed these results (Figure 2B). Not totally consistent with the reduced expression of the mexB, the MIC against aztreonam of ARP36 containing mexRCSP18 was decreased only twofold (Table 1), not to the level of CSP18. Plasmids expressing the mexRCSP18 or mexRARP36 were further respectively introduced into the CSP18 strain background. As the results shown in Figures 2B,C and Table 1, overexpression of mexRARP36, but not mexRCSP18, resulted in significant increases in β-galactosidase activity, mexB mRNA level, and MIC against aztreonam. These data demonstrated that the R70Q substitution in MexR is the cause of dramatic increase in the expression of mexAB-oprM seen in the ARP36 strain.
The fact that wild-type mexR (mexRCSP18) was unable to restore the MIC against aztreonam in ARP36 to the level of CSP18 suggested that either some other factors may also be involved or the MexRARP36 functions dominant over MexRCSP18. To test this possibility, the chromosomal mexR gene of the CSP18 strain was replaced by mexRARP36. As shown in Table 1, replacement of the mexRCSP18 with mexRARP36 conferred the CSP18 strain the same MIC against aztreonam as the ARP36 strain. Agreeing with the recovered MIC to aztreonam of CSP18mexRARP36, transcriptional level of mexAB-oprM was also increased to that of ARP36 (Figures 2D,E). These data demonstrated that R70Q substitution in the MexR is responsible for the reduced susceptibility to aztreonam in strain ARP36 and further indicated that the MexR (R70Q) encoded by the ARP36 displays a dominant negative effect over the functional MexRCSP18.
R70Q Substitution Prevents MexR From Binding to the Intergenic Region Between mexR and mexAB-oprM Operon
MexR binds as a dimer to the intergenic region between mexR and mexAB-oprM operon to repress their expressions (; ). The R70Q substitution in MexR resulted in a dramatic increase in the expression of mexAB-oprM in the ARP36 strain. This prompted us to test the binding capability of MexR (R70Q) to the target sequence. EMSA was performed using a fragment between mexR and mexAB-oprM operon which contains two MexR-binding sites (). MexRCSP18 and MexRARP36 were expressed in E. coli BL21 (DE3), purified with Ni-NTA (Figure 3A), and used for EMSA. As shown in Figure 3B, band shift was detected when DNA fragments were incubated with MexRCSP18, but not MexRARP36, indicating that MexRAPR36 lost its binding capability to the target sequence. To further confirm this result, MST experiment was carried out with NT-647-NHS-labeled MexR as aptamer probes. As the results shown in Figure 3C, the binding between MexRCSP18 and mexR-mexA intergenic region was detected with a Kd of 1.1 μM, while the binding of MexRARP36 was undetectable. These results further confirmed that MexR with a R70Q substitution compromised its binding capability to the mexR-mexA intergenic region. Notably, some other mutations in MexR, such as L57P, L57R, T69I, etc., also render MexR unable to bind to its DNA binding region ().
FIGURE 3
As MexR forms homodimer for DNA binding (; ), we want to ask if the impaired binding capability of MexRARP36 was due to the abolished dimerization. To assess the possibility, we utilized a bacterial two-hybrid system to assess MexR dimerization. The mexR genes from CSP18 and ARP36 were respectively cloned into both the pTRG and pBT vectors. The interactions between each two protein pairs were assessed by the β-galactosidase activity in the reporter strains. Test results showed positive interaction between MexRARP36 and MexRARP36 or MexRCSP18 and MexRARP36, indistinguishable with that between MexRCSP18 and MexRCSP18 (Figure 3D). These data demonstrated that R70Q substitution had no apparent impact on the dimerization of MexR and provided a possible explanation for the dominance of MexRARP36 over MexRCSP18. Of note, L95F or R21W substitution in MexR had been shown to have no apparent impact on MexR dimerization and be dominant over the wild-type MexR when coexpressed in P. aeruginosa ().
In fact, a R70W mutation in MexR in nalB strain OCR1 has been reported to lead to overexpression of mexAB-oprM (). Similar to many other nalB strains, OCR1 strain produced little or no detectable MexR protein (). Similarly, a R73C substitution in MarR, another member of MarR family regulator, resulted in a low protein amount when expressed in E. coli BL21 (DE3) (). However, in our study, similar MexR protein amounts were observed between MexRCSP18 (MexRWT) and MexRARP36 (MexRR70Q) when expressed in E. coli BL21 (DE3) (Figure 3A), indicating the different effect on MexR stability mediated by MexRR70Q and MexRR70W.
The three-dimensional structure of MexR and MarR has been solved with X-ray crystallography (; Wilkinson and Grove, 2006). The critical biophysical properties of MexR and its well-established set of mexR mutations, including R70W substitution, have been analyzed (). MexR lacks tryptophan, while has 12 arginines. In addition, R70W and R70Q substituted MexR exerted different effects on the MexR stability. Therefore, the three-dimensional structure of R70Q mutant of MexR was further modeled based on the crystal structure of the MexR in its open form (PDB entry 1LNW) (), as shown in Figure 4. It is suggested that this mutation on alpha helix4, or the DNA recognition helix, could have profound effect on disrupting the DNA-binding conformation in two possible manners: (i) the mutant may break the electrostatic interaction formed by the originally positively charged Arg70 and the phosphate group of the binding DNA; (ii) this mutation may also alter the conformation of α helix4 on two protomers of the MexR dimer, and consequently lead to a narrower groove which is incompatible with DNA binding. However, this mutant may not significantly alter the dimeric assembly as α helix4 has not been shown as a structural element for dimerization. To further explore the molecular basis for the changed regulation mode as observed in this study, the crystal structure of the R70Q mutant should be determined.
FIGURE 4
There are numerous regulators that have been shown to influence the expression of mexAB-oprM operon genes. In addition to the MexR, NalD, a second repressor, represses the expression of mexAB-oprM directly by binding to its second promoter (). NalC, a repressor of armR, regulates mexAB-oprM expression through repressing the expression of ArmR, which can bind to and prevent MexR binding to the promoter region of mexAB-oprM (). CpxR, a two-component response regulator, and BrlR, a MerR-like regulator, positively regulate mexAB-oprM expression by directly binding to its promoter region (; Tian et al., 2016). MdrR1 (PA3898) and MdrR2 (PA2100) directly repress the expression of mexAB-oprM multidrug efflux pump independent of the MexR (). MexT, a LysR-type regulator, and RocA2, a two-component system regulator, exert a negative regulatory effect on mexAB-oprM genes (; ). However, all the genes mentioned above are identical between CSP18 and ARP36 (data not shown), thus were not the cause for the increased expression of mexAB-oprM in ARP36.
Statements
Data availability statement
The raw data for both RNAseq and genome resequencing have been upload to the NCBI, under the accession number: PRJNA681301. And the data can be found under the link below: https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA681301.
Ethics statement
We have a waiver from the medical ethics committee of Tianjin Union Medical Center, exempting this study from the requirement to have ethics approval and written informed consent as the clinical strains used in this work come from the routine procedures of the clinical laboratory rather than the clinical trials.
Author contributions
YJ conceived, designed the experiments, and wrote the manuscript. ZM, CX, XZ, DW, XP, HL, and GZ performed the experiments. YJ, FB, ZC, and WW analyzed the data. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the National Science Foundation of China (31870130, 31670130, 81670766, and 31970680), the Science and Technology Committee of Tianjin (19JCYBJC24700), National Key Research and Development Project of China (2017YFE0125600), the International Cooperation and Exchange of the National Natural Science Foundation of China (82061148018), and the Science and Technology Program of Sichuan Province (2018JZ0069).
Acknowledgments
We are grateful for Prof. Lu Zhang from ShanghaiTech University China for help with structural analysis of the MexR dimer.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.659808/full#supplementary-material
Supplementary Table 1Bacterial strains and plasmids used in this study.
Supplementary Table 2Primers used in this study.
Supplementary Table 3Transcriptome analysis: differentially expressed genes by RNAseq.
Supplementary Table 4Genomic mutations identified by genome resequencing with elimination of SNVs with synonymous mutation and the same mutations between CSP18 and ARP36.
References
1
AdewoyeL.SutherlandA.SrikumarR.PooleK. (2002). The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity.J. Bacteriol.1844308–4312. 10.1128/jb.184.15.4308-4312.2002
2
AlekshunM. N.KimY. S.LevyS. B. (2000). Mutational analysis of MarR, the negative regulator of marRAB expression in Escherichia coli, suggests the presence of two regions required for DNA binding.Mol. Microbiol.351394–1404. 10.1046/j.1365-2958.2000.01802.x
3
AndrésenC.JalalS.AiliD.WangY.IslamS.JarlA.et al (2010). Critical biophysical properties in the Pseudomonas aeruginosa efflux gene regulator MexR are targeted by mutations conferring multidrug resistance.Protein Sci.19680–692. 10.1002/pro.343
4
BerrazegM.JeannotK.Ntsogo EnguénéV. Y.BroutinI.LoeffertS.FournierD.et al (2015). Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa isolates to Antipseudomonal Cephalosporins.Antimicrob. Agents Chemother.596248–6255. 10.1128/aac.00825-15
5
BrogdenR. N.HeelR. C. (1986). Aztreonam. a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs3196–130. 10.2165/00003495-198631020-00002
6
BurnsJ. L.GibsonR. L.McNamaraS.YimD.EmersonJ.RosenfeldM.et al (2001). Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.J. Infect. Dis.183444–452. 10.1086/318075
7
CaoL.SrikumarR.PooleK. (2004). MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719.Mol. Microbiol.531423–1436. 10.1111/j.1365-2958.2004.04210.x
8
ChoudhuryD.GhoseA.Dhar ChandaD.Das TalukdarA.Dutta ChoudhuryM.PaulD.et al (2016). Premature termination of MexR leads to overexpression of MexAB-OprM efflux pump in Pseudomonas aeruginosa in a tertiary referral hospital in India.PLoS One11:e0149156. 10.1371/journal.pone.0149156
9
CurranB.JonasD.GrundmannH.PittT.DowsonC. G. (2004). Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa.J. Clin. Microbiol.425644–5649. 10.1128/jcm.42.12.5644-5649.2004
10
DriscollJ. A.BrodyS. L.KollefM. H. (2007). The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections.Drugs67351–368. 10.2165/00003495-200767030-00003
11
ElsonE. C.MermisJ.PolineniD.OermannC. M. (2019). Aztreonam lysine inhalation solution in cystic fibrosis.Clin. Med. Insights Circ. Respir. Pulm. Med.13:1179548419842822. 10.1177/1179548419842822
12
EvansK.AdewoyeL.PooleK. (2001). MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region.J. Bacteriol.183807–812. 10.1128/jb.183.3.807-812.2001
13
Heacock-KangY.SunZ.Zarzycki-SiekJ.PoonsukK.McMillanI. A.ChuanchuenR.et al (2018). Two regulators, PA3898 and PA2100, modulate the Pseudomonas aeruginosa multidrug resistance MexAB-OprM and EmrAB efflux pumps and biofilm formation.Antimicrob. Agents Chemother.62:e01459. 10.1128/aac.01459-18
14
JorthP.McLeanK.RatjenA.SecorP. R.BautistaG. E.RavishankarS.et al (2017). Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa.Mbio8:e00517. 10.1128/mBio.00517-17
15
LiX. Z.NikaidoH.PooleK. (1995). Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa.Antimicrob. Agents Chemother.391948–1953. 10.1128/aac.39.9.1948
16
LiaoJ.SchurrM. J.SauerK. (2013). The MerR-like regulator BrlR confers biofilm tolerance by activating multidrug efflux pumps in Pseudomonas aeruginosa biofilms.J. Bacteriol.1953352–3363. 10.1128/jb.00318-13
17
LimD.PooleK.StrynadkaN. C. (2002). Crystal structure of the MexR repressor of the mexRAB-oprM multidrug efflux operon of Pseudomonas aeruginosa.J. Biol. Chem.27729253–29259. 10.1074/jbc.M111381200
18
ListerP. D.WolterD. J.HansonN. D. (2009). Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance Mechanisms.Clin. Microbiol. Rev.22582–610. 10.1128/cmr.00040-09
19
LivermoreD. M.JamrozyD.MushtaqS.NicholsW. W.YoungK.WoodfordN. (2017). AmpC β-lactamase induction by avibactam and relebactam.J. Antimicrob. Chemother.723342–3348. 10.1093/jac/dkx298
20
MahenthiralingamE.CampbellM. E.FosterJ.LamJ. S.SpeertD. P. (1996). Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis.J. Clin. Microbiol.341129–1135. 10.1128/jcm.34.5.1129-1135.1996
21
MasedaH.SawadaI.SaitoK.UchiyamaH.NakaeT.NomuraN. (2004). Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa.Antimicrob. Agents Chemother.481320–1328. 10.1128/aac.48.4.1320-1328.2004
22
McLeanK.LeeD.HolmesE.PenewitK.WaalkesA.RenM.et al (2019). In vivogenomic analysis identifies Novel Pseudomonas aeruginosa resistance genes under selection during inhaled aztreonam therapy.Antimicrob. agents chemother.63:e00866. 10.1128/aac.00866-19
23
MoritaY.CaoL.GouldV. C.AvisonM. B.PooleK. (2006). nalD encodes a second repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa.J. Bacteriol.1888649–8654. 10.1128/jb.01342-06
24
NakaeT. (1995). Role of membrane permeability in determining antibiotic resistance in Pseudomonas aeruginosa.Microbiol. Immunol.39221–229. 10.1111/j.1348-0421.1995.tb02193.x
25
NikaidoH. (1994). Prevention of drug access to bacterial targets: permeability barriers and active efflux.Science264382–388. 10.1126/science.8153625
26
OermannC. M.McCoyK. S.Retsch-BogartG. Z.GibsonR. L.McKevittM.MontgomeryA. B. (2011). Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).J. Antimicrob. Chemother.662398–2404. 10.1093/jac/dkr303
27
O’SullivanB. P.YasothanU.KirkpatrickP. (2010). Inhaled aztreonam.Nat. Rev. Drug Dis.9357–358. 10.1038/nrd3170
28
PooleK.TetroK.ZhaoQ.NeshatS.HeinrichsD. E.BiancoN. (1996). Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.Antimicrob. Agents Chemother.402021–2028. 10.1128/aac.40.9.2021
29
QualeJ.BratuS.GuptaJ.LandmanD. (2006). Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.Antimicrob. Agents Chemother.501633–1641. 10.1128/aac.50.5.1633-1641.2006
30
RichardotC.JuarezP.JeannotK.PatryI.PlesiatP.LlanesC. (2016). Amino acid substitutions account for Most MexS alterations in clinical nfxC mutants of Pseudomonas aeruginosa.Antimicrob. Agents Chemother.602302–2310. 10.1128/aac.02622-15
31
SaitoK.AkamaH.YoshiharaE.NakaeT. (2003). Mutations affecting DNA-binding activity of the MexR repressor of mexR-mexA-mexB-oprM operon expression.J. Bacteriol.1856195–6198. 10.1128/jb.185.20.6195-6198.2003
32
SaitoK.YoneyamaH.NakaeT. (1999). nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome.FEMS Microbiol. Lett.17967–72. 10.1111/j.1574-6968.1999.tb08709.x
33
SchweizerH. P. (1992). Allelic exchange in Pseudomonas aeruginosa using novel ColE1-type vectors and a family of cassettes containing a portable oriT and the counter-selectable Bacillus subtilis sacB marker.Mol. Microbiol.61195–1204. 10.1111/j.1365-2958.1992.tb01558.x
34
SivanesonM.MikkelsenH.VentreI.BordiC.FillouxA. (2011). Two-component regulatory systems in Pseudomonas aeruginosa: an intricate network mediating fimbrial and efflux pump gene expression.Mol. Microbiol.791353–1366. 10.1111/j.1365-2958.2010.07527.x
35
SobelM. L.HocquetD.CaoL.PlesiatP.PooleK. (2005). Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa.Antimicrob. Agents Chemother.491782–1786. 10.1128/aac.49.5.1782-1786.2005
36
SpilkerT.CoenyeT.VandammeP.LiPumaJ. J. (2004). PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients.J. Clin. Microbiol.422074–2079. 10.1128/jcm.42.5.2074-2079.2004
37
SrikumarR.PaulC. J.PooleK. (2000). Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa.J. Bacteriol.1821410–1414. 10.1128/jb.182.5.1410-1414.2000
38
TianZ. X.YiX. X.ChoA.O’GaraF.WangY. P. (2016). CpxR Activates MexAB-OprM efflux pump expression and enhances antibiotic resistance in both laboratory and clinical nalB-type isolates of Pseudomonas aeruginosa.PLoS Pathog.12:e1005932. 10.1371/journal.ppat.1005932
39
WengY.ChenF.LiuY.ZhaoQ.ChenR.PanX.et al (2016). Pseudomonas aeruginosa enolase influences bacterial tolerance to oxidative stresses and virulence.Front. Microbiol.7:1999. 10.3389/fmicb.2016.01999
40
WilkinsonS. P.GroveA. (2006). Ligand-responsive transcriptional regulation by members of the MarR family of winged helix proteins.Curr. Issues Mol. Biol.851–62.
41
XuC.LiuH.PanX.MaZ.WangD.ZhangX.et al (2020a). Mechanisms for development of ciprofloxacin resistance in a clinical isolate of Pseudomonas aeruginosa.Front. Microbiol.11:598291. 10.3389/fmicb.2020.598291
42
XuC.WangD.ZhangX.LiuH.ZhuG.WangT.et al (2020b). Mechanisms for rapid evolution of carbapenem resistance in a clinical isolate of Pseudomonas aeruginosa.Front. Microbiol.11:1390. 10.3389/fmicb.2020.01390
43
ZhengR.FengX.WeiX.PanX.LiuC.SongR.et al (2018). PutA is required for virulence and regulated by PruR in Pseudomonas aeruginosa.Front. Microbiol.9:548. 10.3389/fmicb.2018.00548
44
Ziha-ZarifiI.LlanesC.KöhlerT.PechereJ. C.PlesiatP. (1999). In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM.Antimicrob. Agents Chemother.43287–291. 10.1128/aac.43.2.287
Summary
Keywords
Pseudomonas aeruginosa, aztreonam resistance, mexR, MexAB-OprM, mutation
Citation
Ma Z, Xu C, Zhang X, Wang D, Pan X, Liu H, Zhu G, Bai F, Cheng Z, Wu W and Jin Y (2021) A MexR Mutation Which Confers Aztreonam Resistance to Pseudomonas aeruginosa. Front. Microbiol. 12:659808. doi: 10.3389/fmicb.2021.659808
Received
28 January 2021
Accepted
17 May 2021
Published
24 June 2021
Volume
12 - 2021
Edited by
Yuji Morita, Meiji Pharmaceutical University, Japan
Reviewed by
Stephen Salipante, University of Washington, United States; Oana Ciofu, University of Copenhagen, Denmark
Updates
Copyright
© 2021 Ma, Xu, Zhang, Wang, Pan, Liu, Zhu, Bai, Cheng, Wu and Jin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongxin Jin, yxjin@nankai.edu.cn
†These authors have contributed equally to this work
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.